Novo Nordisk, Wegovy

Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several other conditions.
With new Wegovy data in hand, Novo Nordisk will file for approval in MASH
Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.
Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study.
Novo Nordisk’s semaglutide shows superior MASH resolution improvement in trial
Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial
Semaglutide shows improvement in liver disease treatment in late stage trial
A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis without worsening steatohepatitis,
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
STAT4d
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
Novo Nordisk Shares Seen Outpacing Lilly’s After Summer Stumble
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...
Novo Nordisk posts Phase 3 win for obesity drug in MASH
Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Charting, Price Performance, News & Related Contracts.
Novo Nordisk: Be Cautious About Buying The Dip
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
Novo Nordisk Reports Positive ESSENCE Trial Results
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that ...
FiercePharma3d
Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant
Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...